HRAS and cancer: Most common mutations (n = 45) involved RAS genes, which were associated with a diagnosis of cancer or NIFTP in 72% for HRAS, 52% for NRAS, and 40% for KRAS. Twenty-two nodules were positive for copy number alterations alone.